INHIBRX BIOSCIENCES, INC. — Income Charts
3 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$1M
R&D
$113M
D&A
$2M
Operating Income
$-135M
EBITDA
$-133M
Interest Expense
$12M
Other Income/Expense
$7M
Pretax Income
$-140M
Tax Provision
$2K
Net Income
$-140M
Operating Margin
-10386.5%
Net Margin
-10773.5%
Effective Tax Rate
-0.0%
Deferred Tax Assets
$1M
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$53M
Tax Credit Carryforwards
$8M
NOL Carryforwards
$40M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
Operating Lease Cost
$4M
Revenue YoY Variation
550.0%
Income YoY Variation
59.3%